The announcement of positive initial results for SP-26, a novel treatment for chronic pain and fibromyalgia, is likely to increase investor confidence in Silo Pharma. The absence of serious side effects is a positive indicator for the drug's future approval and market potential. This news could lead to a short-term increase in Silo Pharma's stock price as investors react to the potential of SP-26.